Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.

@article{Zamboni2011BidirectionalPI,
  title={Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.},
  author={William C. Zamboni and Lauren J. Maruca and Sandra A. Strychor and Beth A. Zamboni and Suresh Ramalingam and Robert Edwards and Jk Kim and Yj Bang and Hy De Lee and David M. Friedland and Ronald G. Stoller and Chandra Prakash Belani and Ramesh K. Ramanathan},
  journal={Journal of liposome research},
  year={2011},
  volume={21 2},
  pages={158-65}
}
BACKGROUND  STEALTH(®) liposomal CKD-602 (S-CKD602), a camptothecin analog, is eliminated by the reticuloendothelial system (RES), which consists of cells, including monocytes. We evaluated the relationship between monocyte and absolute neutrophil counts (ANCs) in the blood and pharmacokinetic disposition of S-CKD602 and nonliposomal CKD-602 (NL-CKD602) in patients. METHODS  As part of a phase I study of S-CKD602 and phase I and II studies of NL-CKD602, the percent decreases in ANC and… CONTINUE READING